Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07732907) titled 'Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia' on July 24.
Study Type: Observational
Primary Sponsor: Bristol-Myers Squibb
Condition:
Multiple Sclerosis
Progressive Multifocal Leukoencephalopathy
Intervention:
Drug: Ozanimod
Recruitment Status: Recruiting
Date of First Enrollment: June 4, 2026
Target Sample Size: 15
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07732907
Disclaimer: Curated by HT Syndication....